INVITED REVIEW

Anti-inflammatory, antiapoptotic, and antioxidant activity of fluoxetine

Vitor Caiaffo¹, Belisa D. R. Oliveira², Fabrício B. de Sá¹ & Joaquim Evêncio Neto¹

¹Department of Animal Morphology and Physiology, Federal Rural University of Pernambuco, Brazil
²Department of Physiotherapy, Caruaruense Association of Higher Education, Brazil

Keywords
Antiapoptotic, anti-inflammatory, antioxidant, Fluoxetine

Correspondence
Vitor Caiaffo, Departamento de Morfologia e Fisiologia Animal, Universidade Federal Rural de Pernambuco, Rua Dom Manoel de Medeiros, s/n, Dois Irmãos, CEP: 52171-900, Recife, Pernambuco, Brazil. Tel: + 55 81 33206346; Fax: +55 81 33206346; E-mail: vcaiaffo@gmail.com

Funding Information
No funding information provided.

Received: 7 January 2016; Revised: 3 March 2016; Accepted: 5 March 2016
Pharma Res Per, 4(3), 2016, e00231, doi:10.1002/prp2.231
doi: 10.1002/prp2.231

Abstract
Fluoxetine is a selective serotonin uptake inhibitor that has been widely used to determine the neurotransmission of serotonin in the central nervous system. This substance has emerged as the drug of choice for the treatment of depression due to its safer profile, fewer side effects, and greater tolerability. Studies have found the following important functions of fluoxetine related to the central nervous system: neuroprotection; anti-inflammatory properties similar to standard drugs for the treatment of inflammatory conditions; antioxidant properties, contributing to its therapeutic action and an important intracellular mechanism underlying the protective pharmacological effects seen in clinical practice in the treatment of different stress-related adverse health conditions; and antiapoptotic properties, with greater neuron survival and a reduction in apoptosis mediators as well as oxidative substances, such as superoxide dismutase and hydrogen peroxide. The aim of this study was to perform a review of the literature on the important role of fluoxetine in anti-inflammatory, cell survival, and neuron trophicity mechanisms (antiapoptotic properties) as well as its role regarding enzymes of the antioxidant defense system.

Abbreviations
BDNF, brain-derived neurotrophic factor; CAT, catalase; CREBcAMP, response element binding protein; FDA, Food and Drug Administration; HOCl, hypochlorous acid; IFN, interferon; IL, interleukin; MDA, Malondialdehyde; NO, nitric oxide; ROS, reactive oxygen species; SOD, superoxide dismutase; TAS, antioxidant status; TNF, tumor necrosis factor.

Introduction
Fluoxetine first emerged in the scientific literature as Lilly 110140 (in hydrochloride form) as a selective serotonin uptake inhibitor (Wong et al. 1974). Following more than 20 years of extensive investigations, serotonin uptake inhibition continues to be the main mechanism of action for fluoxetine, which is a pharmacological agent that has been widely used to determine the neurotransmission of serotonin in the central nervous system (Wong et al. 1995). Evidence from the early 1970s demonstrated that fluoxetine had potential in the treatment of depression (Wong et al. 1974). Since its approval from the US Food and Drug Administration (FDA) on December 29th, 1987, Prozac (the commercial name for fluoxetine) has become the most widely prescribed antidepressant in the world. In 1994, the FDA approved a second clinical use for fluoxetine in the treatment of obsessive-compulsive disorder and the members of the FDA Advisory Committee unanimously recommended the approval of fluoxetine for the treatment of bulimia in April of that same year (Wong et al. 1995).

Fluoxetine is the drug of choice for the treatment of depression due to its safer profile, fewer side effects, and greater tolerability (Wilde and Benfield 1998). Studies have found important functions of fluoxetine related to the central nervous system. Zhang et al. (2012) discovered a neuroprotective function of this drug against microglial activation due to neurotoxicity in neurons. Novio et al. (2011) demonstrated a positive effect of fluoxetine against...
anti-inflammatory action

It has recently been demonstrated that depression is associated with the activation of the inflammatory response system (Makkonen et al. 2011), as evidence has demonstrated an increase in the production of proinflammatory cytokines, such as interleukin-1β (IL-1β), IL-6 and interferon-γ (IFN-γ) (Maes 1999; Makkonen et al. 2011). An increase in the production of IL-1 and IL-2 has been found in the supernatant of mitogen-stimulated splenocyte cultures from rats submitted to chronic stress and rat depression models (Seidel et al. 1995; Kubera et al. 1996). Yirmiya (1996) and Maes (1999) suggest that the increase in the production of proinflammatory cytokines may play a role in the etiology of depression. Indeed, IL-1, IL-6, and IFN-γ in experiments involving animals and humans have been found to produce behavioral changes and symptoms similar to those found in depression, such as an inability to feel pleasure, anorexia, weight loss, withdrawal from social situations, psychomotor retardation, a lack of energy, irritability, and sleep disorders (Makkonen et al. 2011).

As proinflammatory cytokines are involved in the etiology of depression, one may expect that antidepressants have negative immunomodulating effects. Prolonged treatment with antidepressants suppresses the response in the acute phase among patients with depression (Yirmiya 1996) as well as rat models of depression involving mild chronic stress (Maes et al. 1997). In experimental inflammation models, fluoxetine has been found to exert anti-inflammatory and pain relief effects. However, the mechanism by which this drug reduces inflammation remains unclear (Song and Leonard 1994).

Abdel-Salam et al. (2004) induced edema in rat paws with the administration of carrageenan and used fluoxetine (either alone or in combination with non-steroidal anti-inflammatory drugs, other antidepressants or melatonin) and found that the intraperitoneal administration of fluoxetine alone suppressed the edema in a dose-dependent fashion. Likewise, when fluoxetine was administered in conjunction with non-steroidal anti-inflammatory drugs (indomethacin, celecoxib, and rofecoxib), other antidepressants (imipramine and trazodone) or melatonin, the combination led to a reduction in inflammation, suggesting that fluoxetine is a useful drug for combating inflammatory processes, especially when administered in conjunction with other specific drugs.

The administration of desipramine in rats increases the capacity of splenocytes to produce the negative immune-regulating cytokine IL-10 (Bianchi et al. 1994). Ex vivo studies have demonstrated that antidepressants inhibit the secretion of IL-1β, IL-2, tumor necrosis factor alpha (TNF-α), and IFN-γ as well as inhibit the proliferative activity of T cells and the cytotoxic activity of natural killer cells (Bianchi et al. 1994; Makkonen et al. 2011). The coincubation of whole blood from health human subjects and either clomipramine, which is a tricyclic antidepressant, or sertraline, which is a selective serotonin uptake inhibitor, diminishes the production of IFN-γ and increases the production of IL-10 (Makkonen et al. 2011). IFN-γ is a proinflammatory cytokine produced by activated T lymphocytes and natural killer cells that stimulates the production of IL-1 and IL-6 (Xia et al. 1996). IL-10 is produced by T-helper lymphocytes, B lymphocytes, and monocytes and has important anti-inflammatory and immunosuppressive properties through the suppression of IFN-γ and other proinflammatory cytokines (Xia et al. 1996). Thus, the IFN-γ to IL-10 ratio produced by immune cells is of fundamental importance to the determination of the capacity to activate or inhibit the functions of monocytes and T lymphocytes (Cavaillon 1996).

Analyzing young adults and elderly individuals with treatment-resistant depression, Kubera et al. (2001) found that the administration of fluoxetine significantly reduced the production of IFN-γ, especially in the elderly subjects, and that the production of IL-10 was significantly greater among the individuals treated with this antidepressant.
In microglia subjected to activation by lipopolysaccharide, Liu et al. (2011) demonstrated that fluoxetine promotes a decrease in production of IL-6, TNF-α, and nitric oxide (NO). These authors also demonstrated that the molecular mechanism that fluoxetine acts is through a decrease in the gene expression observed by reducing the transcription levels of mRNA of IL-6 and TNF-α. Furthermore, fluoxetine may also act by inhibiting the phosphorylation of mitogen activated protein kinase, important signaling pathway of proinflammatory cytokines, and activation of nuclear factor kappaB (NF-kB), a significant inflammatory signaling molecule. Likewise, Ghosh et al. (2015) found a change in the levels of IL-4, IL-6, IL-10, and IL-12 in macrophages maintained in a culture of fluid tumor cells. This change in the levels of these cytokines shows an altered activation of macrophages with a possible phenotypic change in M1 macrophages (classic) to M2 (changed). After supplementation with fluoxetine, these authors demonstrated significant reversal of IL-4 levels, IL-6, and IL-10 for similar to the control group. These authors declare that fluoxetine can act on the reversal of polarization of modified macrophages by inhibition of NF-kB, strongly suggesting that fluoxetine can be an effective agent able to reprogram macrophages in favor of the host undergoing inflammatory conditions.

Thus, these studies cited demonstrate the importance of fluoxetine to the activation of the anti-inflammatory response system.

**Antiapoptotic action**

The role of intracellular signaling molecules, transcription factors, and chromatin-modifying enzymes has been highlighted in the physiopathology and treatment of mood disorders (Kubera et al. 2001). Special attention has been given to apoptotic processes, which are programmed and controlled by the balance between proapoptotic (e.g., BAD) and antiapoptotic (e.g., Bcl-2) molecules (Covington et al. 2010).

Bcl-2 attenuates apoptosis by promoting cell survival as well as axon growth and neuron regeneration (Cory and Adams 2002). The expression of Bcl-2 is controlled by different factors involved in survival pathways, such as brain-derived neurotrophic factor (BDNF) and the response element to AMPc cAMP response element-binding protein (CREB). This expression can be regulated by stress, antidepressants, and antipsychotics (Park et al. 2006; Drzyzga et al. 2009; Hammonds and Shim 2009). Moreover, it has been demonstrated that antidepressants overregulate the expression of Bcl-2 (Xu et al. 2003; Kock et al. 2009). Curiously, the stimulation of BDNF also activates the protein kinase B, which is also known as Akt (Chiou et al. 2006). The Akt protein complex is involved in the neuron structure, cell survival, and cell death through apoptosis and also stimulates the expression of Bcl-2, thereby inhibiting apoptosis (Lawlor and Alessi 2001; Huang and Reichardt 2003).

Using fluoxetine and olanzapine either alone or combined, Réus et al. (2012) found an increase in Akt, CREB, BDNF, Bcl-2, and BAD in the frontal cortex, hippocampus, and striatum nucleus of adult rats. These areas are very much involved in mood disorders and depression. Bcl-2 belongs to a family of proteins that regulate programmed cell death. The control of the apoptotic process is achieved by the balance between proapoptotic (e.g., BAD and BAX) and antiapoptotic (e.g., Bcl-2 and Bcl-XL) proteins (Hammonds and Shim 2009). An increase in proapoptotic over antiapoptotic proteins is associated with greater susceptibility to cell death (Lawlor and Alessi 2001). Thus, Réus et al. (2012) suggest an antiapoptotic effect of treatment with fluoxetine and olanzapine.

It has been demonstrated that Bcl-2 is a repressor of neuron death (Myers et al. 1995; Lindsten et al. 2005). Both Bcl-2 and BAD regulate the release of cytochrome c, which plays a role in the onset of apoptosis (Li et al. 1997). Agostinho et al. (2011b) evaluated the effects of fluoxetine and olanzapine on mitochondrial respiratory chains and found that the two drugs, either alone or in conjunction, alter the activity of these chains in the brain of rats. Moreover, acute treatment with fluoxetine alters the activity of the enzyme citrate synthase and both acute and chronic treatments modify the activity of the enzyme creatine kinase (Agostinho et al. 2009, 2011a). These enzymes are involved in cell metabolism and the relationship between fluoxetine and energy metabolism has been clearly demonstrated, which is correlated with neuropsychiatric disorders (Ben-Shachar and Karry 2008; Quiroz et al. 2008).

Besides controlling cell survival, the antiapoptotic protein Bcl-2 also exerts a neurotrophic effect (Jonas et al. 2003). Studies report that some antidepressants (e.g., fluoxetine) and stress regulate neurotrophic factors, such as CREB and BDNF, which are involved in cell survival pathways and control the expression of proapoptotic and antiapoptotic proteins (Manji et al. 2001). Kosten et al. (2008) found that repeated, unpredictable stress reduces the mRNA levels of Bcl-2 in the central nucleus of the amygdala in the cingulate gyrus and frontal cortices. In contrast, treatment with antidepressants, such as fluoxetine, reboxetine, and tranylcypromine, overregulates the expression of Bcl-2 in the same areas of the brain (Quiroz et al. 2008). Huang et al. (2007) also found that desipramine inhibits the induction of IL-1β and IL-6 mediated by the modulation of Bcl-2. Moreover, it has been demonstrated that the administration of olanzapine regulates the expression of Bcl-2 RNAm in the hippocampus of rats (Bai et al. 2004).
Likewise, Ghosh et al. (2015) have demonstrated an increase in apoptosis in T cells as evidenced by increased annexin-positive cells and cells with mitochondrial depolarization. These changes represent the development of an immunosuppressive condition caused by fluid tumor used. These adverse conditions were reversed by supplementation with fluoxetine, strengthening the immunoregulatory role of this antidepressant. In order to assess the status of pro / antiapoptotic markers within these T cells, this study evaluated the intracellular level of caspase-3 and Bcl-2, respectively, and it was found a reduction in caspase-3 expression with concomitant increase in the level of Bcl-2 in these cells with supplementation of fluoxetine. This result suggests an antiapoptotic role of fluoxetine.

The overregulation of CREB regulates the transcription of Bcl-2 (Lonze and Ginty 2002). The expression of Bcl-2 is also stimulated by the activation of Akt, thereby inhibiting apoptosis (Gerber et al. 1999). Studies have demonstrated that cortical regions exhibit a reduction in the function of Akt among depressed individuals (Hsiung et al. 2003; Karege et al. 2007) and reduced Akt levels are also found in the brain of schizophrenic patients (Emanmian et al. 2004). Réus et al. (2012) found that the combination of fluoxetine and olanzapine leads to an increase in Akt levels in the prefrontal cortex. Nakano et al. (2010) found that treatment with BDNF also stimulates the phosphorylation of Akt. Réus et al. (2012) found that high levels of Bcl-2 due to the administration of fluoxetine may be involved in the activation of CREB through signaling by Akt. Indeed, the Bcl-2 promoter gene has an element that is responsive to AMPc (CRE), which, when phosphorylated (CREB), binds to mRNA and increases the transcription of the antiapoptotic protein (Belkkhiri et al. 2008).

Overregulated CREB can activate targets, such as BDNF, following the use of antidepressants (Nibuya et al. 1996). Treatment with the combination of fluoxetine and olanzapine has been found to raise BDNF and CREB levels in rats; however, the administration of fluoxetine alone at a dose of 12.5 mg/Kg leads to a greater increase in BDNF (Réus et al. 2012). In contrast, Shishkina et al. (2012) found that levels of BDNF and proapoptotic proteins (e.g., BAX) were unaltered with the administration of fluoxetine or due to stress. However, high BDNF levels were found in the dentate gyrus of the hippocampus when combining treatment with fluoxetine and ketanserin, which is an antagonist of the serotoninergic receptor 5-HT(2A) (Pilar-Cuellar et al. 2012). The authors suggest that the effect of fluoxetine on BDNF is related to the type of treatment, administration protocol, and area of the brain. Réus et al. (2012) also found that the effects of fluoxetine are dependent on the dosage and area of the brain. The authors explain this dependent effect by the fact that the brain has dissimilar areas and distinct areas have different proteins and cell metabolisms.

Although several studies show antiapoptotic effects of fluoxetine, Djordjevic et al. (2011) found a positive relationship of Bax/Bcl-2 in rats livers stress induced and treated with fluoxetine. These authors report that the prevalence of Bax in relation to the Bcl-2 can be interpreted as an activation of the apoptotic response under treatment with fluoxetine. These authors also found increased DNA fragmentation in animal cells treated with fluoxetine. This DNA fragmentation can be due to a greater decrease in Bcl-2 than the increase in Bax. These results corroborate the findings of Zhai et al. (2009) that demonstrated an increased apoptosis after administration of fluoxetine. Due to this apoptotic potential of fluoxetine, Serafeim et al. (2003) considers it as a promising therapeutic agent for Burkitt’s lymphoma.

**Antioxidant action**

Central nervous tissue has a high percentage of phospholipids, such as arachidonic acid, docosahexaenoic acid, inositol phosphate, and diacylglycerol, which are easily peroxidized, consequently generating reactive oxygen species (ROS). These phospholipids are generated as secondary messengers by neurotransmitters (e.g., dopamine, serotonin, glutamate, and acetylcholine) normally involved in the etiopathology of diseases of the central nervous system (Mahadik and Evans 2003).

Free radicals are very reactive species that have an unpaired electron. This large group of molecules is mainly represented by the superoxide radical (O_2•^-), peroxy radical (ROO•^-), hydroxyl radical (OH•^-), and NO•^- These molecules and their respective byproducts, such as hydrogen peroxide (H_2O_2) and hypochlorous acid (HOCl), are considered ROS (Dröge 2002; Valko et al. 2007). The overproduction of ROS results in an imbalance in prooxidant and antioxidant processes, which lead to the phenomenon known as oxidative stress. Oxidative stress is harmful to lipids, proteins, nucleic acids, and other cell structures. This process alters the normal cell metabolism and can even lead to cell death. The process of lipid peroxidation, which also results in the production of free radicals, is the most well-known harm caused by oxidative stress (Hwang and Kim 2007). Malondialdehyde (MDA) is the most widely studied product of lipid peroxidation. This aldehyde is a highly toxic molecule that interacts with proteins and DNA and is considered mitogenic. Studies addressing lipid peroxidation in patients with depression describe an increase in MDA levels and other products of lipid peroxidation (Tsuboi et al. 2006; Sarandol et al. 2007; Galecki et al. 2009).
Different biochemical processes can raise the number of ROS, characterizing some central nervous system conditions, such as depression. One of these processes is the increase in glutaminergic transduction and an increase in the concentration of glutamate to toxic levels (Lee et al. 2002). The prolonged activation of neurons by glutamate can be harmful due to the consequent production of ROS (Hendriks et al. 2005).

Studies have found that individuals with depression have high levels of proinflammatory substances, such as IL-1, IL-2, IL-6, and TNF-α (Schiepers et al. 2005; Raison et al. 2006). These cytokines, especially IL-1, increase the activity of the hypothalamus–hypophysis–adrenal system, thereby increasing the number of free radicals (Lee et al. 2002). A depressive state stimulates immune cells, such as neutrophils, macrophages, monocytes, astrocytes, and microglia (Tsuboi et al. 2006). These cells interact with proinflammatory cytokines, resulting in the production of free radicals (Guzik et al. 2003). Based on the inflammatory components involved in the etiology of depression, researchers have suggested that antidepressants act on proinflammatory cytokines (Brustoiilm et al. 2006).

There is little information regarding the influence of fluoxetine on antioxidant enzymes. While some studies suggest that this antidepressant restores the antioxidant capacity in the brain (Bilici et al. 2001; Novio et al. 2011), Djordjevic et al. (2011) suggested that the fluoxetine affects liver antioxidant system of rats and other studies report that such therapy does not significantly alter this capacity in patients with depression (Tsuboi et al. 2006).

The primary antioxidant defense system involves the coordinated effects of some enzymes, such as SOD, catalase (CAT), GPx, and GR, which have consistently been studied in individuals with depression (Ng et al. 2008). Using mice submitted to stress, Moretti et al. (2012) found a reduction in the activity of CAT and GR, especially in the hippocampus, as well as GR in the cerebral cortex, indicating a change in the antioxidant defense system in the nervous system of these animals. A reduction in CAT activity is associated with a large amount of H₂O₂ available to react with transcription metals and generate the most harmful radical (hydroxyl), resulting in an increase in lipid peroxidation and subsequent neuron damage (Meister and Anderson 1983). As glutathione is the main non-protein antioxidant molecule and a major redox regulator that protects the nervous system against ROS (Moretti et al. 2012), reductions in glutathione levels and GR activity lend support to the notion that stress induces an increase in oxidative damage in the brain of rats. Based on such evidence, Moretti et al. (2012) suggest that the significant oxidative damage is found in authors’ studies was evidenced by the increase in lipid peroxidation in the hippocampus and cerebral cortex, resulting from reductions in CAT (hippocampus and cerebral cortex) and GR (hippocampus) activity as well as glutathione levels (cerebral cortex). Using ascorbic acid and fluoxetine as treatment, the same authors demonstrated prevention against induced stress, suggesting a reduction in lipid peroxidation in the hippocampus, mainly by avoiding a reduction in CAT activity. These findings are consistent proof of the antioxidant effects of antidepressants, as the damage evaluated in plasma, serum, and blood cells was reversed following treatment with classic antidepressants, such as fluoxetine, suggesting that the antioxidant properties of these medications contribute to an improvement in clinical aspects (Bilici et al. 2001; Khanzode et al. 2003; Herken et al. 2007).

However, Djordjevic et al. (2011) found a decrease in SOD activity, a noninterference in the CAT activity, increased activity of GPx, increased GR activity, and an increase in the antioxidant status (TAS) in the liver of rats subjected to chronic stress and treated with fluoxetine. According to Souza et al. (1994), fluoxetine directly affects the structure of the mitochondrial membrane of hepatocytes, generating an increase in lipid peroxidation. With decreased SOD, primarily responsible for the prevention of lipid peroxidation, GPx rises and emerges as a compensatory response to increased peroxidation. The antioxidant effect of fluoxetine reported in many studies—can also be due to the fact that this drug increases serotonin levels which exhibit antioxidant effects (Huether and Schuff-Werner 1996). However, Djordjevic et al. (2011) claim that the increase in TAS can serve as an indicator of increased liver oxidative damage.

Adverse stimuli, such as stress and anxiety, can induce peripheral oxidative stress by increasing the production of ROS in lymphocytes, granulocytes, and monocytes (Rammal et al. 2008). Analyzing mice treated with fluoxetine, Novio et al. (2011) found a partial improvement in the adverse effects caused by induced stress. This improvement is associated with the restorative capacity of fluoxetine with regard to endogenous components of the antioxidant defense system (SOD, CAT, and diaphorase) as well as the restoration of non-enzymatic antioxidant components, such as glutathione, thereby demonstrating that fluoxetine is capable of attenuating oxidative damage produced by stress in the peripheral immune system.

The oxidant/antioxidant relationship is an important determinant of cellular immunological function (Rammal et al. 2008). A reduction in antioxidant status favors the accumulation of free radicals. This leads to oxidative stress and the possible apoptosis of immune cells, such as neutrophils (Meydani et al. 1995), which can be prevented by CAT and glutathione. Considering the fundamental role of immune cells in the protection of the organism, these findings lend support to theory that...
stressed animals are predisposed to recurring infections and chronic inflammation as well as other adverse health conditions (Rahman and Macnee 2000; Kowalska et al. 2003; Halliwell 2006).

Novio et al. (2011) and Djordjevic et al. (2011) found that fluoxetine alone promotes a change in the antioxidant status of non-stressed animals, meaning that this antidepressant may not alter the antioxidant defense status in the absence of oxidative stress. This finding suggests that fluoxetine has an antioxidant effect only under conditions of oxidative damage.

**Final Considerations**

The findings of this study demonstrate that fluoxetine exerts a significant effect on the improvement of defense systems, with the overregulation of the production of anti-inflammatory cytokine, the production of antioxidant enzymes, and the modulation of the cell apoptosis cascade. This drug also acts on the inhibition of the release of proinflammatory cytokines as well as the reduction in the expression of prooxidant enzymes and free radicals. Thus, this study reports the important anti-inflammatory, antiapoptotic, and antioxidant functions of fluoxetine and suggests that the clinical benefits of its administration are related to the cell-modulating functions in the central and peripheral nervous systems.

**Disclosure**

The authors declare no conflicts of interest.

**References**

Abdel-Salam OME, Baiumoy AR, Arbid M (2004). Studies on the anti-inflammatory effect of fluoxetine in the rat. Pharmacol Res 49: 119–131.

Agostinho FR, Scaini G, Ferreira GK, Jeremias IC, Réus GZ, Rezin GT, et al. (2009). Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Res Bull 80: 337–340.

Agostinho FR, Réus GZ, Stringari RB, Ribeiro KA, Benedet J, et al. (2011a). Treatment with olanzapine, fluoxetine and olanzapine/fluoxetine alters citrate synthase activity in rat brain. Neurosci Lett 487: 278–281.

Agostinho FR, Réus GZ, Stringari RB, Ribeiro KA, Ferreira GK, Jeremias IC, et al. (2011b). Olanzapine plus fluoxetine treatment alters mitochondrial respiratory chain activity in the rat brain. Acta Neuropsychiatr 23: 282–291.

Bai O, Zhang H, Li XM (2004). Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 1010: 81–86. Belkkhiri A, Dar AA, Zaïka A, Kelley M, El-Rifai W (2008). Darp promotes cancer cell survival by up-regulation of Bcl2 through Akt dependent mechanism. Cancer Res 68: 395–403.

Ben-Shachar D, Karry R (2008). Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS ONE 3: 1–13.

Bianchi M, Sacerdote P, Panerai AE (1994). Fluoxetine reduces inflammatory edema in the rat: involvement of the pituitary-adrenal axis. Eur J Pharmacol 263: 81–84.

Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O (2001). Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 63: 43–51.

Brustoilim D, Ribeiro-Dos-santos R, Kast R, Altschuler E, Soares M (2006). A new chapter opens in anti-inflammatory treatments: The antidepressants bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol 6: 903–907.

Cavaillon JM (1996). Les cytokines. Masson, Paris.

Chiou SH, Ku HH, Tsai TH, Lin HL, Chen LH, Chien CS, et al. (2006). Moclubemide upregulated Bcl-2 expression and induced neural stem cell differentiation into sero-toninergic neuron via extracellular regulated kinase pathway. Br J Pharmacol 148: 587–598.

Cory S, Adams JM (2002). The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647–656.

Covington HE, Vialou V, Nestler EJ (2010). From synapse to nucleus: novel targets for treating depression. Neuropharmacology 58: 683–693.

Djordjevic J, Djordjevic A, Adzic M, Elakovic I, Matic G, Radojci MB (2011). Fluoxetine affects antioxidant system and promotes apoptotic signaling in Wistar rat liver. Eur J Pharmacol 659: 61–66.

Dröge W (2002). Free radicals in the physiological control of cell function. Physiol Rev 82: 47–95.

Drzyzga LR, Marcinowska A, Ohuchowicz E (2009). Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies. Brain Res Bull 79: 248–257.

Emamian ES, Hall D, Birnbaum MJ, Karayargou M, Gogos JA (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36: 131–137.

Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E (2004). Studies on the anti-inflammatory effect of fluoxetine in the rat brain. Acta Neuropsychiatr 23: 282–291.

Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E (2006). Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 86.

Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E, Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E (2006). Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 86.

Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E, Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E (2006). Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 86.
kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273: 30336–30343.

Ghosh S, Mukherjee S, Choudhury S, Gupta P, Adhikary A, Baral R, et al. (2015). Reactive oxygen species in the tumor niche triggers altered activation of macrophages and immunosuppression: role of fluoxetine. Cell Signal 27: 1398–1412.

Guzik TJ, Korbut R, Adamek-Guzik T (2003). Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54: 469–487.

Halliswell B (2006). Phagocyte-derived reactive species: salvation or suicide? Trends Biochem Sci 31: 509–515.

Hammonds MD, Shim SS (2009). Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 105: 113–119.

Hendriks J, Teunissen CH, de Vries H, Dijkstra CH (2005). Macrophages and neurodegeneration. Brain Res Rev 48: 185–195.

Herken H, Gurel A, Selek S, Armutcu F, Ozen ME, Bulut M, et al. (2007). Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 38: 247–252.

Hsiung SC, Adlersberg M, Arango V, Mann JJ, Tamir H, Liu KP (2003). Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase. J Neurochem 87: 182–194.

Huang E, Reichardt LF (2003). Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72: 609–642.

Huang YY, Peng CH, Yang YP, Wu CC, Hsu WM, Wang HJ, et al. (2007). Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. J Pharmacol Sci 105: 113–119.

Huether G, Schuff-Werner P (1996). Platelet serotonin acts as a locally releasable antioxidant. Adv Exp Med Biol 398: 299–306.

Hwang ES, Kim GH (2007). Biomarkers of oxidative stress status of DNA, lipids, and proteins in vitro and in vivo cancer research. Toxicology 229: 1–10.

Jonas EA, Hoit D, Hickman JA, Brandt TA, Polster BM, Fannjiang Y, et al. (2003). Modulation of synaptic transmission by the BCL-2 family protein BCL-xL. J Neurosci 23: 8423–8431.

Karege F, Porrud N, Burkhardt S, Schwald M, Ballmann E, la Harpe R, et al. (2007). Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 15: 240–245.

Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R (2003). Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8: 365–370.

Kock JM, Hinze-Selch D, Stingle K, Huchzermeier C, Goder R, Seeck-Hirschner M, et al. (2009). Changes in CREB phosphorylation and BDNF plasma levels during psycho-therapy of depression. Psychother Psychosom 78: 187–192.

Kolla N, Wei Z, Richardson JS, Li XM (2005). Amitriptyline and fluoxetine protect PC2 cells from cell death induced by hydrogen peroxide. J Psychiatry Neurosci 30: 196–201.

Kosten TA, Galloway MP, Duman RS, Russel DS, D’Sac C (2008). Repeated unpredictable stress and antidepressants differentially regulate expression of the Bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 3: 545–558.

Kowalska M, Kowalska H, Zawadzka-Glos L, Debska M, Szerszen E, Chmielik M, et al. (2003). Dysfunction of peripheral blood granulocyte oxidative metabolism in children with recurrent upper respiratory tract infections. Int J Pediatr Otorhinolaryngol 67: 365–371.

Kubera M, Symbirtsev A, Basta-Kaim A, Borycz J, Roman A, Papp M, et al. (1996). Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol 48: 503–506.

Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M (2001). Anti-Inflammatory Effects of Antidepressants Through Suppression of the Interferon-α/Interleukin-10 Production Ratio. J Clin Psychopharmacol 21: 199–206.

Lawlor M, Alessi D (2001). PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114: 2903–2910.

Lee AL, Wo O, Sapolsky RM (2002). Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 4: 117–128.

Li P, Nijhawan D, Budihardjo I, Srinivasasula SM, Ahmad M, Alnemri ES, et al. (1997). Cytochrome c and dATP dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479–489.

Lindsten T, Zong WX, Thompson CB (2005). Defining the role of the Bcl-2 118 family of proteins in the nervous system. Neuroscientist 11: 10–15.

Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A (2011). Anti-inflammatory effects of fluoxetine in lipopolysaccharide (LPS)-stimulated microglial cells. Neuropharmacology 61: 592–599.
Lonze BE, Ginty DD (2002). Function and regulation of CREB family transcription factors in the nervous. Neuron 35: 605–623.

Maes M (1999). Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461: 25–46.

Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, et al. (1997). Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 15: 1–11.

Mahadik SP, Evans DR (2003). Is Schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implication. Psychiatr Clin North Am 26: 85–102.

Makkonen L, Kokki H, Kuikka J, Turpeinen U, Riikonen R (2011). Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-1 in children with autism. Neuropediatrics 42: 207–209.

Manji HK, Drevets WC, Charney DS (2001). The cellular neurobiology of depression. Nat Med 7: 541–547.

Meister A, Anderson ME (1983). Glutathione. Annu Rev Biochem 52: 711–760.

Meydani SN, Wu D, Santos MS, Hayek MG (1995). Antioxidants and immune response in aged persons: overview of present evidence. Am J Clin Nutr 62: 1462S–1476S.

Moretti M, Colla A, Balen GO, Santos DB, Budni J, Freitas AE, et al. (2012). Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. J Psychiatr Res 46: 331–340.

Myers KM, Fiskum G, Liu Y, Simmons SJ, Bredesen DE, Murphy AN (1995). Bcl-2 protects neural cells from cyanide/aglycemia-induced lipid oxidation, mitochondrial injury, and loss of viability. J Neurochem 65: 2432–2440.

Nakano M, Osada K, Misonoo A, Fujisawa K, Takahashi M, Ogawa Y, et al. (2010). Fluvox- amine and serotonin receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells. Life Sci 86: 309–314.

Ng F, Berk M, Dean O, Bush AI (2008). Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11: 851–876.

Nibuya M, Nestler EJ, Duman RS (1996). Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in the rat hippocampus. J Neurosci 16: 2365–2372.

Novio S, Nunez MJ, Amigo G, Freire-Garabal M (2011). Effects of fluoxetine on the oxidative status of peripheral blood leukocytes of restri nstressed mice. Basic Clin Pharmacol Toxicol 109: 365–371.

Park SW, Lee SK, Kim JM, Yoon JS, Kim YH (2006). Effects of quetiapine on the brain- derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci Lett 402: 25–29.

Pilar-Cuellar F, Vidal R, Pazos A (2012). Subchronic treatment with fluoxetine and ketan- serin increases hippocampal brain-derived neurotrophic factor, b-catenin and antidepressant-like effects. Neuropsychopharmacology 62: 177–183.

Quiroz JA, Gray AN, Kato T, Manji HK (2008). Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33: 2551–2565.

Rahman I, Macnee W (2000). Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 16: 534–554.

Raison CL, Capuron L, Miller AH (2006). Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27: 24–31.

Rammal H, Bouayed J, Younos C, Soulimani R (2008). The impact of high anxiety level on the oxidative status of mouse peripheral blood lymphocytes, granulocytes and monocytes. Eur J Pharmacol 589: 173–175.

Rüs GZ, Abelaria HM, Agostinho FR, Ribeiro KF, Vitto MF, Luciano TF, et al. (2012). The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain. J Psychiatr Res 46: 1029–1035.

Sarandol A, Sarandol E, Eker S, Erdinc S, Vatansever E, Kirli S (2007). Major depressive disorder is accompanied with oxidative stress: shortterm antidepressant treatment does not alter oxidative-antioxidative system. Hum Psychopharmacol 22: 67–73.

Schiepers OJ, Wichers MC, Maes M (2005). Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29: 201–217.

Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H (1995). Cytokine production and serum proteins in depression. Scand J Immunol 41: 534–538.

Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, et al. (2003). Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101: 3212–3219.

Shishkina GT, Kalinina TS, Berezova IV, Dygalo NN (2012). Stress induced activation of the brainstem Bcl-xL gene expression in rats treated with fluoxetine: correlations with serotonin metabolism and depressive-like behavior. Neuropsychopharmacology 62: 177–183.

Song C, Leonard BE (1994). An acute phase protein response in the ol- factory bulbectomized rat: effect of sertraline treatment. Med Sci Res 22: 313–314.

Souza ME, Polizello AC, Uyemura SA, Castro-Silva O, Curti C (1994). Effect of fluoxetine on rat liver mitochondria. Biochem Pharmacol 48: 535–541.
Tsuboi H, Tatsumi A, Yamamoto K, Kobayashi F, Shimoi K, Kinae N (2006). Possible connection among job stress, depressive symptoms, lipid modulation and antioxidants. J Affect Disord 9: 63–70.

Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007). Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44–84.

Wilde MI, Benfield P (1998). Fluoxetine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics 13: 543–561.

Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB (1974). A selective inhibitor of serotonin uptake lilly 110140, 3- (ptrifluoromethylphenoxy)-n-methyl-3-phenylpropylamine. Life Sci 15: 471–479.

Wong DT, Bymaster FP, Engleman EA (1995). Prozac (Fluoxetine, lilly 128 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci 57: 411–441.

Xia Z, Depierre JW, Nassberger L (1996). Tricyclic antidepressants inhibit IL-6, IL-1beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 34: 27–37.

Xu H, Steven RJ, Li XM (2003). Dose-related effects of chronic antidepressants on neuro- protective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 28: 53–62.

Yirmiya R (1996). Endotoxin produces a depressive-like episode in rats. Brain Res 711: 163–174.

Zafir A, Banu N (2007). Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol 572: 23–31.

Zhai FG, Zhang XH, Wang HL (2009). Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats. Clin Exp Pharmacol Physiol 36: 850–856.

Zhang F, Zhou H, Wilson BC, Shi J, Hong J, Gao H (2012). Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord 18: S213–S217.